Somatic BRCA1 loss-of-function in HER2-negative metastatic breast: TBCRC-048 (Tung 2020)...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BRCA1-SOMATIC-BREAST |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-BREAST |
| Sources | SRC-CIVIC SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 |
Actionability Facts
| Biomarker | BIO-HRR-PANEL |
|---|---|
| Variant | BRCA1 somatic loss-of-function |
| Disease | DIS-BREAST |
| ESCAT tier | IB |
| Recommended combinations | talazoparib monotherapy (off-label, NCCN-listed), olaparib monotherapy (off-label) |
| Evidence summary | Somatic BRCA1 loss-of-function in HER2-negative metastatic breast: TBCRC-048 (Tung 2020) showed talazoparib activity in sBRCA tumors (ORR ~31%). PARPi labels in breast are formally germline-only (gBRCAm); somatic tumors treated off-label or via NCCN extrapolation. ESCAT IB / OncoKB Level 2. |
Notes
Off-label PARPi use; reflex germline testing recommended. Distinguish BRCA1 promoter methylation (epigenetic, also actionable) from somatic mutation.
Used By
No reverse references found in the YAML corpus.